证券代码：002370 证券简称：亚太药业 公告编号：2025-074 浙江亚太药业股份有限公司 关于公司 2025 年度向特定对象发行股票摊薄即期回报、采 取填补措施及相关主体承诺的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 浙江亚太药业股份有限公司（以下简称"公司"或"亚太药业"）第八届董 事会第五次会议审议通过了向特定对象发行 A 股股票（以下简称"本次发行"） 的相关议案，公司拟向特定对象发行 A 股股票募集资金不超过 70,000.00 万元（含 70,000.00 万元）。 根据《国务院关于进一步促进资本市场健康发展的若干意见》（国发〔2014〕 17 号）《国务院办公厅关于进一步加强资本市场中小投资者合法权益保护工作的 意见》（国办发〔2013〕110 号）以及《关于首发及再融资、重大资产重组摊薄 即期回报有关事项的指导意见》（证监会公告〔2015〕31 号）的相关要求，为保 障中小投资者的利益，公司就本次向特定对象发行股票对即期回报摊薄的影响进 行了分析，并结合实际情况制定了填补被摊薄即期回报的具体措施，相关主体对 公司填补回报措施能 ...

浙江亚太药业股份有限公司（以下简称"亚太药业"或"公司"）系深圳证 券交易所主板上市公司。为满足公司经营战略的实施和业务发展的资金需求，增 强公司的资本实力和盈利能力，根据《中华人民共和国公司法》《中华人民共和 国证券法》和《上市公司证券发行注册管理办法》等有关法律、法规和规范性文 件及《浙江亚太药业股份有限公司章程》的规定，公司编制了《浙江亚太药业股 份有限公司 2025 年度向特定对象发行股票发行方案论证分析报告》（以下简称 "本论证分析报告"）。 证券简称：亚太药业 证券代码：002370 浙江亚太药业股份有限公司 2025 年度向特定对象发行股票 发行方案论证分析报告 二〇二五年十月 在全球人口老龄化趋势日益加剧、医药研发支出持续增加以及医药技术不断 革新等多重因素的共同驱动下，全球及中国医药市场近年来呈现出强劲且持续的 增长势头，并预计在未来十年内仍将维持较高的增长速度。 本论证分析报告中如无特别说明，相关用语具有与《浙江亚太药业股份有限 公司 2025 年度向特定对象发行股票预案》中相同的含义。 一、本次向特定对象发行股票的背景和目的 （一）本次发行股票的背景 1、全球和中国医药市场需求保持增长， ...

证券代码：002370 证券简称：亚太药业 公告编号：2025-083 浙江亚太药业股份有限公司 关于 2025 年度向特定对象发行 A 股股票预案披露的 提示性公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 浙江亚太药业股份有限公司（以下简称"亚太药业"或"公司"） 于 2025 年 10 月 13 日召开第八届董事会第五次会议，审议通过了关 于公司 2025 年度向特定对象发行 A 股股票的相关议案。具体内容详 见 2025 年 10 月 14 日公司在指定信息披露媒体《证券时报》和巨潮 资讯网（www.cninfo.com.cn）上刊载的《浙江亚太药业股份有限公 司 2025 年度向特定对象发行股票预案》及相关公告，敬请投资者注 意查阅。 公司本次向特定对象发行股票预案的披露事项不代表审批机关 对本次向特定对象发行股票相关事项的实质性判断、确认或批准，预 案所述本次向特定对象发行 A 股股票相关事项的生效和完成尚需取 得公司股东大会审议通过、深圳证券交易所审核通过及中国证券监督 管理委员会同意注册后方可实施，本次发行能否成功实施尚存在不确 定性。公 ...

股票代码：002370 股票简称：亚太药业 Zhejiang Yatai Pharmaceutical Co., Ltd （浙江省绍兴市柯桥区群贤路 2003 号 1501 室） 2025 年度向特定对象发行股票 募集资金可行性分析报告 二〇二五年十月 浙江亚太药业股份有限公司 2025 年度向特定对象发行股票募集资金可行性分析报告 浙江亚太药业股份有限公司（以下简称"公司"、"亚太药业"）是一家在深 圳证券交易所上市的公司，股票简称为"亚太药业"，股票代码为 002370.SZ。 为满足公司业务发展的资金需求，增强公司的资本实力和盈利能力，根据《中华 人民共和国证券法》（以下简称"《证券法》"）、《中华人民共和国公司法》（以下 简称"《公司法》"）、《上市公司证券发行注册管理办法》（以下简称"《注册管理 办法》"）第九条、第十条、第十一条、第十三条、第四十条、第五十七条、第六 十条有关规定的适用意见——证券期货法律适用意见第 18 号（以下简称"《证 券期货法律适用意见第 18 号》"）等有关法律、行政法规、部门规章和《公司章 程》的规定，公司编制了 2025 年度向特定对象发行股票募集资金可行性分析报 告 ...

国联民生证券承销保荐有限公司 关于 浙江亚太药业股份有限公司 详式权益变动报告书 之 财务顾问核查意见 二〇二五年十月 国联民生承销保荐财务顾问核查意见 声 明 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司收 购管理办法》《公开发行证券的公司信息披露+内容与格式准则第15号——权益 变动报告书》《公开发行证券的公司信息披露内容与格式准则第16号——上市 公司收购报告书》等法律法规的规定，国联民生证券承销保荐有限公司按照证 券行业公认的业务标准、道德规范和勤勉尽责精神，对本次信息披露义务人披 露的《浙江亚太药业股份有限公司详式权益变动报告书》进行核查，并出具核查 意见。 为使相关各方恰当地理解和使用本核查意见，本财务顾问特别声明如下： 1、本财务顾问已按照规定履行了尽职调查义务，对信息披露义务人披露的 《详式权益变动报告书》进行了核查，确信披露文件内容与格式符合规定，并保 证所发表的专业意见与信息披露义务人披露内容不存在实质性差异； 2、本财务顾问所依据的有关资料由信息披露义务人提供。信息披露义务人 已做出声明，保证其所提供的所有文件、材料及口头证言真实、准确、完整、及 时，不存在任何重大遗漏 ...

Core Viewpoint - Asia-Pacific Pharmaceutical is undergoing a second attempt at a change of control since the "Fubon system" took over in 2021, driven by a harsh reality of six and a half years of negative net profit excluding non-recurring items and cumulative losses exceeding 2.7 billion yuan [1] Group 1: Acquisition and Financial Issues - The company's decline began with a 900 million yuan acquisition of Shanghai New Gaofeng Biopharmaceutical Co., which turned out to be a long-term financial fraud scheme [2] - In 2019, the company reported a net profit loss of 2.069 billion yuan, a year-on-year drop of over 1000% [2] - The Zhejiang Securities Regulatory Bureau found that Shanghai New Gaofeng inflated revenue by 453 million yuan and profits by 174 million yuan from 2016 to 2018 [2] - The original controlling shareholder's debts led to a judicial auction of shares, allowing the "Fubon system" to acquire control for 418 million yuan [2] - A compensation agreement requires the counterparty to pay 256 million yuan in performance compensation and penalties, but this amount remains unpaid as of the 2025 semi-annual report [2] Group 2: Ongoing Financial Struggles - Despite the "Fubon system" takeover, the company has not reversed its operational difficulties, with negative net profit excluding non-recurring items for six consecutive years, totaling over 2.5 billion yuan in losses [3] - In the first half of 2025, the company reported operating revenue of 152 million yuan, a year-on-year decline of 31.48% [3] - Although the net profit attributable to shareholders surged by 1820.97%, this was primarily due to non-recurring gains from the sale of a subsidiary, with the actual net profit excluding this transaction being -48.86 million yuan, a year-on-year drop of 524.31% [3] - The company acknowledged that factors such as national centralized procurement and intensified industry competition have led to declining sales revenue [3] Group 3: Risk of Delisting and Control Change - According to revised delisting rules, companies with negative net profit excluding non-recurring items and revenue below 300 million yuan face delisting risk warnings [4] - Asia-Pacific Pharmaceutical's 2024 revenue was 405 million yuan, with a negative net profit of 28.13 million yuan, nearing the warning threshold [4] - If the company cannot achieve revenue growth and turn around its main business in the second half of the year, it is likely to be classified as "ST" [4] - The change of control is seen as a signal of the "Fubon system" exiting, raising questions about whether the new controlling party has the resources to save the company from delisting [4] Conclusion - The saga of Asia-Pacific Pharmaceutical involves a 900 million yuan acquisition that led to financial fraud, ongoing losses for six years, and a struggle for control that reflects a race against time to avoid delisting [5]

北京商报讯（记者 丁宁）10月8日晚间，亚太药业（002370）发布公告称，公司股票自10月9日开市起 继续停牌，预计停牌时间不超过3个交易日。 公告显示，亚太药业于9月26日收到控股股东宁波富邦控股集团有限公司及一致行动人上海汉贵投资管 理有限公司、实际控制人宋汉平、傅才、胡铮辉组成的管理团队及一致行动人宋凌杰的通知，其正在筹 划公司控制权变更事项，该事项可能导致公司控股股东及实际控制人发生变更。鉴于上述事项处于筹划 阶段，尚存在重大不确定性，为保证公平信息披露，避免公司股价异常波动，维护广大投资者利益，经 公司向深交所申请，公司股票已于9月29日开市起停牌。 亚太药业表示，截至公告披露日，相关各方正在积极推进本次交易的各项工作，公司预计无法在10月9 日上午开市起复牌。经公司向深交所申请，公司股票自10月9日开市起继续停牌，预计停牌时间不超过3 个交易日。 ...

Core Points - Zhejiang Apac Pharmaceutical Co., Ltd. is planning a change in control, which may lead to a change in its controlling shareholder and actual controller [1] - The company's stock will be suspended from trading starting September 29, 2025, for no more than 2 trading days [1] - As of the announcement date on October 9, 2025, the related work is still ongoing, and the company expects to remain suspended from trading for an additional 3 trading days [1] - The company will fulfill its information disclosure obligations as required and will announce and apply for resumption of trading once the matter is determined [1] - There is significant uncertainty regarding this matter, and investors are advised to be cautious [1]

证券代码：002370 证券简称：亚太药业 公告编号：2025-070 浙江亚太药业股份有限公司 关于筹划公司控制权变更进展暨继续停牌的公告 本公司及董事会全体成员保证信息披露内容真实、准确和完 整，没有虚假记载、误导性陈述或者重大遗漏。 特别提示： 1、公司股票（证券简称：亚太药业，证券代码：002370）自 2025 年 10 月 9 日开市起继续停牌，预计停牌时间不超过 3 个交易日。 2、公司控制权变更事项目前处于筹划阶段，尚存在重大不确定 性，敬请广大投资者注意投资风险。 司控制权变更事项的停牌公告》。 二、交易进展情况及继续停牌事项的说明 截至本公告披露日，相关各方正在积极推进本次交易的各项工作， 公司预计无法在 2025 年 10 月 9 日（星期四）上午开市起复牌。 鉴于上述事项存在不确定性，为保证公平信息披露，避免公司股 价异常波动，维护广大投资者利益，根据《深圳证券交易所上市公司 自律监管指引第 6 号——停复牌》等相关规定，经公司向深圳证券交 易所申请，公司股票（证券简称：亚太药业，证券代码：002370）自 2025 年 10 月 9 日（星期四）开市起继续停牌，预计停牌时间不超过 3 ...

Core Viewpoint - Asia-Pacific Pharmaceutical (002370.SZ) is planning a change in control, with its major shareholder, Ningbo Fubon Holding Group, and associated parties notifying the company of this development. This is not the first time the company has considered a change in ownership, as it previously changed hands in 2021 due to financial issues stemming from a 900 million yuan acquisition that led to financial fraud allegations [1][2][4]. Group 1: Company Background and Previous Ownership Changes - Asia-Pacific Pharmaceutical was established in 1989 and went public in 2010, with a product portfolio that includes chemical drug formulations, raw materials, and drug research and development [1]. - In 2015, the company acquired 100% of Shanghai New Gaofeng for 900 million yuan, aiming to enter the high-growth pharmaceutical research service sector. However, this acquisition resulted in significant losses and financial fraud revelations [2][3]. - Following the financial scandal, the original controlling shareholders faced severe financial difficulties, leading to the acquisition of control by the "Fubon Group" through judicial auction in 2021 [3]. Group 2: Financial Performance and Current Challenges - Since the financial scandal in 2019, Asia-Pacific Pharmaceutical has reported cumulative losses exceeding 2.7 billion yuan over six and a half years, with continuous pressure on its core business [4][5]. - The company's revenue from 2019 to 2024 showed a declining trend, with total revenues of 709 million yuan, 515 million yuan, 315 million yuan, 373 million yuan, 421 million yuan, and 405 million yuan respectively. The net profit attributable to shareholders has been negative for six consecutive years [4]. - In the first half of 2025, the company reported approximately 152 million yuan in revenue, a year-on-year decrease of 31.48%, while the net profit attributable to shareholders was approximately 105 million yuan, a year-on-year increase of 1820.97%. However, the non-recurring net profit was negative, indicating core business struggles [4][5]. Group 3: Market Perception and Future Outlook - Despite weak fundamentals, Asia-Pacific Pharmaceutical's stock price surged by 85.9% in 2025, driven by overall market trends in the innovative drug sector and expectations of mergers and acquisitions in the pharmaceutical industry [6]. - The ongoing risks of delisting due to negative net profits and declining revenues highlight the urgency for the company to implement effective operational improvements under new control [5][6].